rhBMP-2 with a demineralized bone matrix scaffold versus autologous iliac crest bone graft for alveolar cleft reconstruction.

Abstract

BACKGROUND:

Secondary alveolar cleft reconstruction using autologous iliac crest bone graft is currently the standard treatment for alveolar clefts. Although effective, harvesting autologous bone may result in considerable donor-site morbidity, most commonly pain and the potential for long-term sensory disturbances. In an effort to decrease patient morbidity, a novel technique using recombinant human bone morphogenetic protein (rhBMP)-2 encased in a demineralized bone matrix scaffold was developed as an alternative to autografting for secondary alveolar cleft reconstruction.

METHODS:

A chart review was conducted for the 55 patients who underwent secondary alveolar cleft reconstruction over a 2-year period with a mean follow-up of 21 months. Of these, 36 patients received rhBMP-2/demineralized bone matrix scaffold (including 10 patients with previously failed repairs using iliac crest bone grafting) and 19 patients underwent iliac crest bone grafting. Postoperatively, bone stock was evaluated using occlusal radiographs rated according to the Bergland and Chelsea scales.

RESULTS:

Alveolar clefts repaired using rhBMP-2/demineralized bone matrix scaffold were 97.2 percent successful compared with 84.2 percent with iliac crest bone grafting. Radiographically, initial repairs with rhBMP-2/demineralized bone matrix scaffold were superior to iliac crest bone grafting according to both Bergland and Chelsea scales, and significantly more patients in the rhBMP-2/demineralized bone matrix scaffold group had coronal bridging. The postoperative intraoral infection rate following iliac crest bone grafting was significantly greater than for rhBMP-2/demineralized bone matrix scaffold. The cost of rhBMP-2/demineralized bone matrix scaffold products was offset by cost savings associated with a reduction in operative time averaging 102 minutes.

CONCLUSIONS:

rhBMP-2 encased in a demineralized bone matrix scaffold appears to be a viable alternative for secondary alveolar cleft repair. Patients are spared donor-site morbidity and achieve excellent results, decreasing operative time, and increasing operating room use.

CLINICAL QUESTION/LEVEL OF EVIDENCE:

Therapeutic, III.

• Authors: Cameron S Francis, Sheila S Nazarian Mobin, Michael A Lypka, Elizabeth Rommer, Stephen Yen, Mark M Urata, Jeffrey A Hammoudeh
• Journal: Plastic and reconstructive surgery (Plast Reconstr Surg) Vol. 131 Issue 5 Pg. 1107-1115 (May 2013) ISSN: 1529-4242 [Electronic] United States
• PMID: 23385986 (Publication Type: Journal Article)

Chemical References

• BMP2 protein, human
• Bone Morphogenetic Protein 2
• Recombinant Proteins

Topics

• Adolescent
• Bone Demineralization Technique (methods)
• Bone Morphogenetic Protein 2 (therapeutic use)
• Bone Transplantation (methods)
• Child
• Cleft Lip (diagnostic imaging, surgery)
• Cleft Palate (diagnostic imaging, surgery)
• Female
• Follow-Up Studies
• Humans
• Ilium (transplantation)
• Male
• Morbidity
• Postoperative Complications (epidemiology, prevention & control)
• Radiography
• Recombinant Proteins (therapeutic use)
• Plastic Surgery Procedures (methods)
• Retrospective Studies
• Tissue Scaffolds